RxDoctor Payments Data

Alyssa Knapp, PA

Medical · Sierra Vista, AZNPI 1346890068

Payments from drug & device makers

$5,087in general payments, 2019–2025

Across 231 payments — averaging $22.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$616
  • AstraZeneca$517
  • AbbVie$468
  • GSK$372
  • Abbott$299
  • Amgen$280
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$4,98898%
  • Education$992%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,087 in reported general payments places this provider in the 85th percentile of 748 medical providers in Arizona.

See all medical providers in Arizona

Medicare billing

Part B allowed, 2024
$52,790
Medicare patients
170
Services billed
641

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab15$106,955
EliquisApixaban79$83,326
OzempicSemaglutide22$29,864
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$23,842
XareltoRivaroxaban20$17,859
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog16$12,835
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$3,751
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$3,655
Gabapentin86$2,928
Venlafaxine Hcl ErVenlafaxine Hcl14$2,243
Atorvastatin Calcium184$2,154
Duloxetine Hcl56$2,153
Nano 2nd Gen Pen NeedlePen Needle, Diabetic16$1,990
Pregabalin23$1,734
Lidocaine12$1,462

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$161$83,32679 claims
Novo NordiskOzempic$616$29,86422 claims
GSKTrelegy Ellipta$372$23,84224 claims
Johnson & JohnsonXarelto$13$17,85920 claims
Lilly USA, LLCHumalog$89$1,20312 claims
AbbVieSynthroid$468$68717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 748 medical providers in Arizona.

Other medical in Sierra Vista

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →